DCA (dichloroacetate) is a naturally occurring, simple and inexpensive compound with significant therapeutic value in disease treatment – especially cancer. DCA use in the treatment of disease is not a new concept.
For more than 30 years, DCA has been used safely and successfully to treat rare metabolic disorders in both children and adults.[1,2]
Recent evidence on the safety and effectiveness of DCA as a cancer treatment makes this novel compound an exciting adjunct in cancer care, especially in those who have advanced (metastatic) and drug-resistant cancers.[3,4]
Oncology experts and researchers agree that one of the biggest challenges facing current and future development of anti-cancer therapy is the difficulty in identifying agents that can selectively induce cancer cell death, but spare normal cells.
Based on the mechanism of DCA’s actions and clinical evidence for its tremendous value in cancer treatment, it fits the desirable criteria for a novel anticancer agent that is selectively targets cancer cells with little to no adverse effects on healthy cells.
DCA is a novel cancer agent because it doesn’t directly kill cancer cells (the standard mechanism of most chemo agents, which renders their significant toxicity). Rather, it alters the unique metabolic features characteristic of cancer cells.[1,7]
Unlike healthy cells, cancer cells produce vast amounts of energy from glucose in a dysfunctional way. Cancer cells have the unique ability to over-express insulin receptors that transport glucose into the cancer cell. Here, via the process of glycolysis – the primary method of energy production for cancer cells – energy is produced from glucose without oxygen (even if oxygen is present).
This phenomenon was first observed by Nobel Prize laureate Otto Warburg in 1929 (known in science as the “Warburg Effect”). 
Rapidly growing tumor cells exhibit rates of glycolysis up to 200 times higher than those of healthy cells. In turn, the energy produced is used to fuel the growth and spread of cancer.
On the other hand, healthy cells do not primarily use glycolysis for energy production, because it’s an inefficient way to produce energy. Instead, healthy cells use oxygen to produce energy from glucose in the mitochondria (the metabolic center) of the cell. The switch to glycolysis as an energy source occurs when cells of a tumor (either benign or pre-cancerous) become deprived of oxygen in their environment.
As a result, their mitochondria cannot work properly. These abnormal cells then ‘switch off’ their mitochondria. Mitochondria are essential to the process of inducing apoptosis (the process by which abnormal cells self-destruct). When cells switch off mitochondria, they develop “immortality” and can continue to divide.
Not all cells of a tumor develop ways to turn off their mitochondria and become immortal. Those that do, outlive the other cells in the tumor and these are the dominant cells that are responsible for the growth, spread (metastasis) and recurrence of disease. DCA specifically targets these dominant cells, producing the clinical observation that most individuals having their disease treated with DCA experience a partial or complete response to treatment and many have achieved stabilization of disease as well as cure.[3,13]
Evangelos Michelakis of the University of Alberta and his colleagues tested DCA on human cells cultured outside the body and found that DCA killed lung, breast and brain cancer cells, while sparing healthy cells.
Tumors in rats deliberately infected with human cancer also shrank drastically when they were fed DCA over several weeks. Results of the study were published in the journal Cancer Cell in 2006. Michelakis’s work proved that DCA re-established proper mitochondrial function in cancer cells, thereby re-engaging the cell’s ability to self-destruct, resulting in cancer cell death (apoptosis).
Results of a small human clinical trial were published in Science Translational Medicine in 2010. Five patients with aggressive brain cancer were treated with DCA. DCA was found to extend the lives of four of the five patients. Brain scans and biopsies demonstrated that DCA arrested the growth of cancer cells by switching them back to normal energy production in the mitochondria.
Colorectal cancer is the third most common cancer in the world and the fourth leading cause of cancer-related death. A study published in the British Journal of Cancer (2010) found DCA caused significant decrease in cancer cell proliferation associated with apoptosis and cell-cycle arrest in colorectal cancer cells.
A study published in 2009 looked at the effects of combination therapy with DCA on hepatocellular carcinoma (HCC). The researchers found the combination therapy synergistically suppressed tumor growth.
There are several published in vivo (cultured cell) and in vitro (human, animal) data on the benefits of DCA in breast cancer, including metastatic disease. [17-19]
At Medicor Cancer Centres (Toronto, Canada), Dr. Khan MD has treated numerous patients with DCA since 2009. He published several papers on the subject and data collection with clinical observation is ongoing. Some published data include:
Other published and unpublished clinical reports from Khan include:
A study published in June 2008 in the journal Gynecology Oncology confirmed that DCA induces apoptosis (cancer cell death) in endometrial cancer cells. Another study, published in 2008 in the journal Prostate found DCA sensitized cancer cells to radiation, enhancing the effects of radiotherapy.
In 2011, the journal Reproductive Science published results of a study that found DCA induced apoptosis of exposed epithelial ovarian cancer cells. Results of an unpublished report demonstrated complete response in stage 4 ovarian cancer when DCA was used in conjunction with carboplatin.
Other cancers successfully treated with DCA (alone or in conjunction with conventional therapies) include: neuroblastoma , lung (carcinoid and non-small cell)[28,20], pancreas, cervical, melanoma, stomach, head and neck, salivary, esophagus, stomach, vaginal and several others.
DCA can be administered orally or by intravenous method. Based on clinical evidence thus far, DCA appears to be more efficacious when given intravenously. In addition, side effects are significantly less with IV DCA than with oral DCA. These observations make IV DCA the preferred method of drug delivery.
IV DCA is administered 2x/wk. Oral DCA is taken 2-3x/day, 2 weeks on and 1 week off.
About 45% of patients will experience side effects to DCA treatment. You must be under the supervision of an ND or MD who is well trained in the delivery and administration of DCA and other cancer natural cancer treatments.
Side effects to DCA are all reversible. With oral DCA, the most common side effects include: peripheral neuropathy (numbness in an area of the body, with or without associated nerve pain; experienced in 15% of patients), fatigue (15%) and confusion/reduced memory (15%). IV DCA has fewer side effects and whatever side effects are experienced, are short-lived. No true allergy to DCA has ever been observed.
If taking cannabinoids and other CNS drugs that cause delirium, DCA must be used cautiously (start with low does and gradually increase).
It is important that the source of DCA be obtained from a reputable supplier for optimal effect and to ensure safety. We obtain our DCA from a reputable source and discourage anyone considering DCA treatment from seeking online or other suppliers of DCA. Those who do, run the serious risk of compromising efficacy, and more importantly, safety of treatment.
Certain natural medicines (such as alpha lipoic acid and several others) act synergistically with DCA and reduce the potential for side effects. Use of the right agents in conjunction with DCA is essential – especially to prevent neuropathy.
Blood work is performed regularly on all our patients receiving DCA or other cancer treatments, in order to monitor safety and efficacy of treatment. These include lab tests such as liver enzymes, markers of kidney function, serum chemistry, complete blood count, glucose levels and relevant tumor markers.
Beyond the anti-cancer effects of DCA, there are additional benefits observed in those who undergo DCA treatment. These include:
Yes, DCA can be safely used with conventional therapies (hormones, chemo, radiation). In fact, research thus far has demonstrated DCA enhances the effectiveness of conventional therapies, generating better response rates and providing more favorable disease outcomes. Most published data indicate it is most effective when used as combination therapy.
To summarize, clinical and scientific findings published to-date, in addition to observational data, indicate that DCA:
Learn more information about early cancer detection tests referred to as the ONCOblot test, CTC’s test referred to as circulation tumour cell test, and cancer biomarker testing by clicking on the words.
We will be in touch within 1 business day.